Edap Tms SA 6-K Filing

FAQ

Key Financial Figures

• $7.7 million — arter of 2025 was €6.7 million (US $7.7 million), compared to €4.5 million (US $4.
• $4.9 million — ion), compared to €4.5 million (US $4.9 million) for the same period in 2024, represent
• $8.4 million — arter of 2025 was €7.2 million (US $8.4 million), compared to €8.6 million (US $9.
• $9.8 million — ion), compared to €8.6 million (US $9.8 million) for the same period in 2024. The expec
• $16.1 million — rter of 2025 was €13.9 million (US $16.1 million), an increase of 6% compared to €1
• $14.4 million — f 6% compared to €13.1 million (US $14.4 million) for the same period in 2024. Gross pr
• $6.9 million — arter of 2025 was €6.0 million (US $6.9 million), compared to €5.2 million (US $5.
• $5.7 million — ion), compared to €5.2 million (US $5.7 million) for the same period in 2024. Gross pro
• $12.7 million — 5 were stable at €10.9 million (US $12.7 million), compared to €11.0 million (US $1
• $12.1 million — on), compared to €11.0 million (US $12.1 million) for the same period in 2024. Operatin
• $6.4 million — ion), compared to €5.8 million (US $6.4 million) for the same period in 2024. Net loss
• $5.8 million — arter of 2025 was €5.0 million (US $5.8 million), or (€0.13) per share, compared t
• $7.0 million — hare, compared to €6.4 million (US $7.0 million), or (€0.17) per share, for the sa
• $23.9 million — er 30, 2025, was €21.3 million (US $23.9 million), an increase of 42% compared to €
• $16.3 million — 42% compared to €15.1 million (US $16.3 million) for the same period in 2024. Non-Core

Filing Documents

• f6k_110625.htm (6-K) — 165KB
• 0001171843-25-007072.txt ( ) — 166KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: November 6, 2025 EDAP TMS S.A. /s/ KEN MOBECK KEN MOBECK CHIEF FINANCIAL OFFICER EDAP Reports Third Quarter 2025 Financial Results 49% YoY HIFU Revenue Growth, Driven by Increased Focal One ® Sales and U.S. Procedure Volumes 167% YoY Growth in Focal One System Placements 15% YoY Growth in U.S. Focal One HIFU Procedures Company to Host Conference Call and Webcast on November 6 at 8:30 a.m. ET AUSTIN, Texas, November 6, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the third quarter of 2025. “Our record-breaking third-quarter revenue performance reflects the continued strong demand for our leading Focal One Robotic HIFU platform, with system placements increasing 167% year over year. Even in a seasonally softer period, we achieved our second consecutive quarter of record HIFU revenue for the respective period, underscoring the consistent and positive growth of our business. It is becoming increasingly clear that more urologists want to offer their patients both an effective and non-invasive treatment option for early-stage prostate cancer. These factors are driving demand as seen over the last two quarters, which reflects this important growing paradigm shift in prostate cancer management. During the quarter we also saw a return to double-digit Focal One procedure growth in the U.S. as we continue to see broader hospital adoption, increased patient demand and expanded insurance provider coverage.” said Ryan Rhodes, Chief Executive Officer of EDAP. “We have also made notable progress strengthening our balance sheet. As announced last month, we finalized an agreement with the European Investment Bank for a €36 million credit facility to

Forward-Looking Statements

Forward-Looking Statements In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”) or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as “believe,” “can,” “contemplate,” “could,” “plan,” “intend,” “is designed to,” “may,” “might,” “potential,” “objective,” “target,” “project,” “predict,” “forecast,” “ambition,” “guideline,” “should,” “will,” “estimate,” “expect” and “anticipate,” or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or d

Forward-looking statements speak only as of the

Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. Investor Contacts Investor Relations EDAP TMS SA investor.relations@focalone.com John Fraunces LifeSci Advisors, LLC (917) 355-2395 jfraunces@lifesciadvisors.com EDAP TMS S.A. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands of Euros and U.S. Dollars, except per share data) Three Months Ended: Three Months Ended: September 30, September 30, September 30, September 30, 2025 2024 2025 2024 Euros Euros $US $US Sales of medical equipment 9,430 8,393 10,958 9,240 Net sales of RPP and leases 2,194 1,586 2,550 1,746 Sales of spare parts, supplies and services 2,255 3,120 2,621 3,435 TOTAL REVENUES 13,879 13,098 16,128 14,420 Cost of sales (7,908 ) (7,944 ) (9,189 ) (8,746 ) GROSS PROFIT 5,972 5,154 6,939 5,675 Research & development expenses (2,086 ) (1,716 ) (2,424 ) (1,889 ) Selling, general & administrative expenses (8,811 ) (9,271 ) (10,239 ) (10,207 ) Total operating expenses (10,898 ) (10,987 ) (12,663 ) (12,096 ) OPERATING LOSS (4,926 ) (5,833 ) (5,724 ) (6,422 ) Interest (expense) income, net (49 ) 102 (57 ) 113 Currency exchange gains (loss), net 64 (606 ) 75 (667 ) LOSS BEFORE INCOME TAXES (4,911 ) (6,337 ) (5,707 ) (6,976 ) Income tax (expense) credit, net (103 ) (62 ) (120 ) (69 ) NET LOSS (5,014 ) (6,399 ) (5,827 ) (7,045 ) Earning per share – basic and diluted (0.13 ) (0.17 ) (0.16 ) (0.19 ) Average number of shares used in computatio

View Full Filing

View this 6-K filing on SEC EDGAR